These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21208909)

  • 1. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
    Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
    Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
    Leroux-Roels G; Bourguignon P; Willekens J; Janssens M; Clement F; Didierlaurent AM; Fissette L; Roman F; Boutriau D
    Clin Vaccine Immunol; 2014 Mar; 21(3):302-11. PubMed ID: 24391139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
    Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
    PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
    Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
    Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
    Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
    Virol J; 2011 May; 8():265. PubMed ID: 21624130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
    Stebbings R; Février M; Li B; Lorin C; Koutsoukos M; Mee E; Rose N; Hall J; Page M; Almond N; Voss G; Tangy F
    PLoS One; 2012; 7(11):e50397. PubMed ID: 23226275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
    Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
    Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
    Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
    Gómez CE; Nájera JL; Perdiguero B; García-Arriaza J; Sorzano CO; Jiménez V; González-Sanz R; Jiménez JL; Muñoz-Fernández MA; López Bernaldo de Quirós JC; Guardo AC; García F; Gatell JM; Plana M; Esteban M
    J Virol; 2011 Nov; 85(21):11468-78. PubMed ID: 21865377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
    Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
    PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
    Lichterfeld M; Gandhi RT; Simmons RP; Flynn T; Sbrolla A; Yu XG; Basgoz N; Mui S; Williams K; Streeck H; Burgett-Yandow N; Roy G; Janssens M; Pedneault L; Vandepapelière P; Koutsoukos M; Demoitié MA; Bourguignon P; McNally L; Voss G; Altfeld M
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):1-9. PubMed ID: 21963936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Tieu HV; Karuna S; Huang Y; Sobieszczyk ME; Zheng H; Tomaras GD; Montefiori DC; Shen M; DeRosa S; Cohen K; Isaacs MB; Regenold S; Heptinstall J; Seaton KE; Sawant S; Furch B; Pensiero M; Corey L; Bar KJ;
    Vaccine; 2023 Oct; 41(42):6309-6317. PubMed ID: 37679276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.